ganagliflozin
ApprovedSmall molecule
ganagliflozin is one of 56 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1ganagliflozin
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Approved
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus1 trial
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 4·NCT07116928·1,244 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ganagliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details